PATENT

Our Docket: P-IM 2442

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: William Soo Hoo Examiner: L. Spector Serial No.: 08/902,516 Group Art Unit: 1646 Filed: July 29, 1997 Batch No.: 183 Date of Notice For: MEMBRANE-BOUND CYTOKINE COMPOSITIONS COMPRISING of Allowance: September 10, 1998 GM-CSF AND METHODS OF I hereby certify that this correspondence is being deposited MODULATING AN IMMUNE RESPONSE with the United States Postal Service as first class mail in an USING SAME envelope addressed to: Honorable Commissioner for Patents, BOX ISSUE FEE, Washington, D.C. 20231, on October 14, 1998. BOX ISSUE FEE Asst. Commissioner for Patents Washington, D.C. 20231

By audrea L. Gashler Andrea L. Gashler, Reg. No. 41,029

> October 14, 1998 Date of Signature

Sir:

STATEMENT UNDER 37 C.F.R. § 1.821(f) and (q)

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR § 1.821(c) and (e), respectively, are the same.

I hereby state that the submission, filed in accordance with 37 C.F.R. § 1.821(g) herein does not include new matter.

Respectfully submitted,

October 14, 1998

Date

Andrea L. Gashler

Registration No. 41,029 Telephone: (619) 535-9001

Facsimile: (619) 535-8949

CAMPBELL & FLORES LLP 4370 La Jolla Village Drive Suite 700 San Diego, California 92122

SEQUENCE LISTING PAGES 57 TO 72 P-IM 2442 Serial No.: 08/902,516

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, BOX ISSUE FEE, Washington, D.C. 20231, on October 14, 1998.

By <u>Audrea L. Gashler</u>, Reg. No. 41,029

October 14, 1998
Date of Signature

Appl	tion	No.	902516	2

NOTICE TO COMPLY WITH K QUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

TXI	
4	1. This application clearly fails to comply with the requirements of 37 CFR 1.8.
	1.825. Applicant's attention is directed to these regulations, published at 114 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
	2 mld a second
	2. This application does not contain, as a separate part of the disclosure on
	paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been
	submitted as required by 37 CFR 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitte
	However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of marked-up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has bee
	found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as requipely 37 CFR 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer
	readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

Applicant must provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the s and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please conta

For Rules Interpretation, call (703) 308-1123 For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.